EUVIMEDEUVIMED entdecken
Fallbericht

Recurrent primary intracranial sarcoma, DICER1-mutant in a pediatric patient with DICER1 syndrome: the importance of molecular testing

Alexandre Lachance, Evan Dimentberg, Sidong Huang, Samuel Bergeron-Gravel, Éric Bouffet, Adriana Fonseca, Louis Crevier, Stephan Saikali, Catherine Bourget, Panagiota Giannakouros, Damien Faury, Nada Jabado und 3 weitere

Child's Nervous System · 2024

DOI: 10.1007/s00381-024-06356-1 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Child's Nervous System, 2024. Verfasst von Alexandre Lachance und 14 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Université Laval, Quebec, Canada. Hauptthemen laut MEDLINE: Ribonuclease III, DEAD-box RNA Helicases, Brain Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pediatric intracranial sarcomas are rare, aggressive tumors with a poor prognosis in general. Here we report the case of a child who was initially diagnosed with a primary intracranial sarcoma, DICER1-mutant; subsequent genetic analyses confirmed a pathogenic germline DICER1 mutation. She received multimodal standard treatments consisting of surgery, radiotherapy and chemotherapy. The tumor recurred 2.5 years later within the surgical cavity. Following the gross tumor resection of this new lesion, the same multimodal standard approach was used. From a molecular perspective, evidence of hyperactivation of the MAPK-kinase pathway with a pathogenic KRAS mutation at both diagnosis and recurrence was present. The patient is currently in remission, 18 months post-end of treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ribonuclease IIIDEAD-box RNA HelicasesBrain NeoplasmsNeoplasm Recurrence, LocalSarcomaHumansFemaleMutationChild

Stichwörter der Autor:innen

DICER1Intracranial sarcomaKRASMAPK

Substanzen

Ribonuclease IIIDEAD-box RNA HelicasesDICER1 protein, human

Autor:innen und Institutionen

  • Faculty of Medicine, Université Laval, Quebec, Canada.
  • Department of Biochemistry, McGill University, Montreal, Canada.
  • Rosalind & Morris Goodman Cancer Institute, McGill University, Montreal, Canada.
  • Division of Radiation Oncology, CHU de Québec - Université Laval, Quebec, Canada.
  • Division of Hematology/Oncology, The Hospital for Sick Children, University of Toronto, Toronto, Canada.
  • Brain Tumor Institute, Children's National Hospital, Washington, USA.

Zitieren

APA

Lachance, A., Dimentberg, E., Huang, S., Bergeron-Gravel, S., Bouffet, É., Fonseca, A., Crevier, L., Saikali, S., Bourget, C., Giannakouros, P., Faury, D., Jabado, N., Foulkes, W. D., Larouche, V., & Renzi, S. (2024). Recurrent primary intracranial sarcoma, DICER1-mutant in a pediatric patient with DICER1 syndrome: the importance of molecular testing. Child's Nervous System. https://doi.org/10.1007/s00381-024-06356-1

Vancouver

Lachance A, Dimentberg E, Huang S, Bergeron-Gravel S, Bouffet É, Fonseca A, et al. Recurrent primary intracranial sarcoma, DICER1-mutant in a pediatric patient with DICER1 syndrome: the importance of molecular testing. Child's Nervous System. 2024. doi:10.1007/s00381-024-06356-1

BibTeX
@article{Lachance2024,
  author = {Lachance, Alexandre and Dimentberg, Evan and Huang, Sidong and Bergeron-Gravel, Samuel and Bouffet, Éric and Fonseca, Adriana and Crevier, Louis and Saikali, Stephan and Bourget, Catherine and Giannakouros, Panagiota and Faury, Damien and Jabado, Nada and Foulkes, William D and Larouche, Valérie and Renzi, Samuele},
  title = {Recurrent primary intracranial sarcoma, DICER1-mutant in a pediatric patient with DICER1 syndrome: the importance of molecular testing},
  journal = {Child's Nervous System},
  year = {2024},
  doi = {10.1007/s00381-024-06356-1}
}
Kostenlos starten →